Abstract is: Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. They are the most common cholesterol-lowering drugs. Low-density lipoprotein (LDL) carriers of cholesterol play a key role in the development of atherosclerosis and coronary heart disease via the mechanisms described by the lipid hypothesis. Statins are effective in lowering LDL cholesterol and so are widely used for primary prevention in people at high risk of cardiovascular disease, as well as in secondary prevention for those who have developed cardiovascular disease. Side effects of statins include muscle pain, increased risk of diabetes mellitus, and abnormal blood levels of liver enzymes. Additionally, they have rare but severe adverse effects, particularly muscle damage. They inhibit the enzyme HMG-CoA reductase which plays a central role in the production of cholesterol. High cholesterol levels have been associated with cardiovascular disease. There are of statins, some of which include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. Combination preparations of a statin and another agent, such as ezetimibe/simvastatin, are also available. The class is on the World Health Organization's List of Essential Medicines with simvastatin being the listed medicine. In 2005, sales were estimated at US$18.7 billion in the United States. The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. The manufacturer Pfizer reported sales of US$12.4 billion in 2008. Due to patent expirations, several statins became available in 2016 as less expensive generics.
| drug class | Q2585617 |
| group or class of chemical entities | Q72070508 |
| medication | Q12140 |
| enzyme inhibitor | Q427492 |
| anticholesteremic agents | Q50429847 |
| oxidoreductase inhibitor | Q66587127 |
| P2581 | BabelNet ID | 00051454n |
| 00051454n | ||
| P6200 | BBC News topic ID | cyxxgj6j31gt |
| P1617 | BBC Things ID | 6b48009e-24ac-4bdc-9123-00b255082954 |
| P683 | ChEBI ID | 87631 |
| P1417 | Encyclopædia Britannica Online ID | science/statin |
| P3219 | Encyclopædia Universalis ID | statines |
| P646 | Freebase ID | /m/0187ml |
| P2924 | Great Russian Encyclopedia Online ID (old version) | 4163904 |
| P7807 | ICD-11 ID (Foundation) | 1210630032 |
| P7329 | ICD-11 ID (MMS) | XM5SK2 |
| P244 | Library of Congress authority ID | sh00001691 |
| P7830 | LiverTox ID | Statins |
| P486 | MeSH descriptor ID | D019161 |
| P672 | MeSH tree code | D27.505.519.186.071.202.370 |
| D27.505.519.389.370 | ||
| D27.505.954.557.500.202.370 | ||
| P6366 | Microsoft Academic ID | 2776839432 |
| P8189 | National Library of Israel J9U ID | 987007285397905171 |
| P3221 | New York Times topic ID | subject/statins-cholesterollowering-drugs |
| P691 | NL CR AUT ID | ph602573 |
| P10283 | OpenAlex ID | C2776839432 |
| C2910980524 | ||
| P1461 | Patientplus ID | lipid-regulating-drugs-including-statins |
| P3417 | Quora topic ID | Statins |
| P5082 | Store medisinske leksikon ID | statiner |
| P4527 | UK Parliament thesaurus ID | 406217 |
| P2892 | UMLS CUI | C0360714 |
| P11143 | WikiProjectMed ID | Statin |
| P2347 | YSO ID | 15649 |
| P361 | part of | response to statin | Q21118078 |
| P910 | topic's main category | Category:Statins | Q8816931 |
| Q126610812 | (3R,5R)-Rosuvastatin |
| Q27163691 | 2,2-dimethylbutanoic acid [8-[2-(4-hydroxy-6-oxo-2-oxanyl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] ester |
| Q27166956 | 7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid |
| Q105206245 | Monacolin K |
| Q417942 | fluvastatin |
| Q417740 | lovastatin |
| Q415159 | rosuvastatin |
| Q670131 | simvastatin |
| Q113897896 | 7-day Simvastatin and Emotional Processing |
| Q113885292 | A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. |
| Q113942080 | A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers |
| Q113922529 | A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study |
| Q113916614 | A Study of Lasmiditan in Healthy Volunteers |
| Q63582605 | A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173) |
| Q61957008 | A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic |
| Q113910331 | A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects |
| Q113939051 | A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants |
| Q63013183 | ANti-Oxidant in Variant Angina (ANOVA) Trial |
| Q61938994 | Additional KIF6 Risk Offers Better Adherence to Statins |
| Q63317735 | Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial) |
| Q113915114 | Anti-inflmmation Treatment in Mood Disorder and Deep Learning Prediction Model |
| Q63317948 | Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation |
| Q61933146 | Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus |
| Q61979393 | Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy |
| Q113919545 | Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease |
| Q113936337 | Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer |
| Q113922372 | Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition |
| Q113945650 | COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS) |
| Q113910501 | Cholesterol Disruption in Combination With FOLFIRINOX in Patients With Metastatic Pancreatic Adenocarcinoma |
| Q113888922 | Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) |
| Q113891502 | Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg |
| Q113914393 | Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study |
| Q113887628 | Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial |
| Q63320466 | Combination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate Cancer |
| Q113888038 | Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial |
| Q61956486 | Community Pharmacy Assisting in Total Cardiovascular Health |
| Q113932351 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study |
| Q113915670 | Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia |
| Q113927779 | Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes |
| Q113923436 | Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients |
| Q113924251 | Cross-over Study of Coronary Risk Factors With a Polypill |
| Q61921448 | Culturally-Tailored Approach to Improve Medication Use in Patients With Heart Attacks |
| Q113898341 | Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD |
| Q87931932 | Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia |
| Q61917444 | Does Statin Therapy Reduce Sympathoexcitation in Hypertension? |
| Q113932548 | Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates |
| Q113944213 | Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin |
| Q113925446 | Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir |
| Q113933394 | Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) |
| Q113928900 | Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants |
| Q61979164 | Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy |
| Q61935772 | Effect of Simvastatin and Ezetimibe on Lipid and Inflammation |
| Q61920557 | Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| Q113939780 | Effect of Statin Therapy on Mortality in Patients With Ventilator Associated Pneumonia |
| Q113912276 | Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI |
| Q63401320 | Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events |
| Q61918535 | Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis |
| Q113894424 | Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial |
| Q113917257 | Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease |
| Q113893582 | Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia |
| Q113893927 | Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia |
| Q113895673 | Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia. |
| Q61975226 | Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia |
| Q113894706 | Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris |
| Q86272507 | Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study |
| Q63577907 | Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline |
| Q113920358 | Efficacy of Simvastatin in Alcoholic Liver Fibrosis |
| Q113919199 | Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer |
| Q113891589 | Endothelial Microparticles as Potential Biomarkers of Endothelial Dysfunction |
| Q62054641 | Epidemiology, Management, Prognosis and Medical Cost Analysis of IHCA and OHCA |
| Q61956580 | Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy |
| Q113916376 | Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in MCI |
| Q63228836 | Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study |
| Q113918035 | Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19 |
| Q113898736 | Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity |
| Q63320881 | Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients |
| Q61981336 | Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED) |
| Q113915570 | HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID) |
| Q63812036 | Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation |
| Q113892534 | Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP) |
| Q113910017 | Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography |
| Q113911381 | Influence of Additional Physician's Consultations and Short Message Service (SMS) Reminders to Patient Compliance |
| Q113914938 | Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study) |
| Q63394197 | Intensive Medical Therapy for High-risk Intracranial or Extracranial Arterial Stenosis |
| Q63339503 | Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI |
| Q113888543 | Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 |
| Q62062594 | Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO] |
| Q102152942 | Lipid Management in Renal Transplant Recipients Using Evolocumab. |
| Q61906885 | Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia |
| Q63322251 | Longitudinal Study of Multi-Analyte Profile for Dyslipidemia |
| Q113890006 | Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI |
| Q63595062 | Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >75 Years: the SCOPE-75 RCT Study |
| Q61969177 | Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients |
| Q63010668 | Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study |
| Q113914227 | Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis |
| Q113889101 | Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma |
| Q63319882 | Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation |
| Q87932762 | Nudges for Statin Prescribing in Primary Care |
| Q113918701 | Oral Statins and Protection From Hearing Loss |
| Q63320367 | Pattern of Statins Use in Catalonia |
| Q113941690 | Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction |
| Q113898442 | Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease |
| Q113891571 | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia |
| Q63340241 | Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe |
| Q113931338 | Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE) |
| Q63572397 | Primary Prevention Program |
| Q63394449 | Primary Prevention With Statin and Incidence of Recurrent MI and Cardiogenic Shock in Post-ACS Patients |
| Q63394451 | Prior Statin Use and Risk of CHF, ALO and Malignant Arrhythmia in Indonesian Post-Acute Coronary Syndrome Patients |
| Q63318311 | Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs |
| Q113944082 | Real World Evidence Study of Statin Use in Brazil |
| Q61907137 | Red Rice Yeast in Low-density Lipoprotein (LDL) Lowering: an Efficacy Study |
| Q113889332 | Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct |
| Q63574930 | STATINS IN Intracerbral Hemorrhage |
| Q113923777 | STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS |
| Q113920458 | Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk |
| Q113899062 | Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions |
| Q63613502 | Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia |
| Q63598047 | Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI) |
| Q63322905 | Statin Discontinuation in Advanced Illness |
| Q113942973 | Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation |
| Q113938992 | Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD |
| Q63572545 | Statin Recapture Therapy Before Coronary Artery Bypass Grafting |
| Q63316166 | Statin Therapy In Cardiac Surgery |
| Q113887442 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer |
| Q113912375 | Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease |
| Q62031370 | Statins and ARBs on Rheumatoid Activity |
| Q89155058 | Statins for Venous Event Reduction in Patients With Venous Thromboembolism |
| Q63402590 | Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study |
| Q63340670 | Statins in Children With Type 1 Diabetes and Hypercholesterolemia |
| Q113944530 | Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome |
| Q107169678 | Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis |
| Q113925417 | Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components |
| Q113923635 | Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients" |
| Q113890205 | Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants |
| Q113911333 | Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia |
| Q113914372 | Supplements, Placebo, or Rosuvastatin Study |
| Q61975375 | TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP) |
| Q113923579 | Technology-Assisted Cholesterol Trial in Consumers (TACTiC) |
| Q113938903 | Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis |
| Q113885214 | The Benefit of Add On DLBS1033 for Ischemic Stroke Patient |
| Q63592084 | The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients |
| Q63580970 | The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial |
| Q113926158 | The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction |
| Q63594832 | The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques |
| Q62104958 | The Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy |
| Q63334231 | The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke |
| Q62062183 | The Impact of Statin Holiday in Dialysis Patients Over 70 Years Old on Mental Function, Physical Function and Frailty |
| Q113926122 | The Interaction of Herbs and Statins |
| Q113893833 | The MASTER Study (MAmmary Cancer STatin ER Positive Study) |
| Q113909871 | The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients |
| Q63335990 | The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage |
| Q113915486 | The Use of Injectable Plasma Versus the Use of Simvastatin Gel in Surgical Management of Bony Defect in Dentistry |
| Q113894155 | To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia |
| Q113931331 | To Study the Safety and Efficacy of Simvastatin in Patients With Hepatopulmonary Syndrome in Cirrhosis. |
| Q63341105 | Treatment of Coronary Heart Disease With Amiloride |
| Q113945716 | Vascular Endothelial Dysfunction in Sleep Apnea |
| Q61934946 | hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP) |
| Q122021943 | Účinný boj s LDL-cholesterolem? Statiny?! |
| Q92807729 | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
| Q44516515 | 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up |
| Q41521183 | 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion |
| Q28317280 | 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 9. The synthesis and biological evaluation of novel simvastatin analogs |
| Q68314031 | 3-Hydroxy-3-methylglutaryldithio-coenzyme A: A potent inhibitor of Pseudomonas mevalonii HMG-CoA reductase |
| Q42214356 | 6-Nitrocholesterol inhibits 3-hydroxy-3-methylglutaryl coenzyme a reductase and tumor cell growth |
| Q37672465 | A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids |
| Q34022421 | A historical perspective on the discovery of statins |
| Q27005638 | A novel therapeutic effect of statins on nephrogenic diabetes insipidus |
| Q26824249 | A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough |
| Q36011053 | A review of time courses and predictors of lipid changes with fenofibric acid-statin combination |
| Q38477549 | A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations |
| Q43447774 | Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit |
| Q38356283 | Action of low-density lipoprotein and compactin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, on the synthesis of dolichol-linked oligosaccharides and low-density-lipoprotein receptor in human skin fibroblasts |
| Q55516148 | Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. |
| Q28327265 | Acute cholestatic hepatitis during simvastatin administration |
| Q56984696 | Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract |
| Q33610712 | American Diabetes Association indications for statins in diabetes: is there evidence? |
| Q35278160 | An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials |
| Q44489379 | An overview: long-term tolerability of lovastatin and simvastatin |
| Q38824464 | Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions |
| Q34151632 | Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels? |
| Q37031349 | Are pleiotropic effects of statins real? |
| Q90020242 | Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins |
| Q67771450 | Associated Effect of Hepatic Hydroxymethylglutaryl Coenzyme A Reductase + Angiotensin Converting Enzyme Inhibitors on the Progression of Renal Failure in Hypertensive Subjects |
| Q64120743 | Association between neurodegenerative diseases and pneumonia: a retrospective population-based study |
| Q64062410 | Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis |
| Q64241736 | Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription |
| Q91041084 | Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis |
| Q33481269 | Associations between statins and COPD: a systematic review. |
| Q28200554 | Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins |
| Q64054125 | Atherosclerotic Coronary Artery Disease in Patients With Cardiometabolic Syndrome |
| Q36897445 | Atorvastatin and cardiovascular risk in the elderly--patient considerations |
| Q26775895 | Atorvastatin treatment improves effects of implanted mesenchymal stem cells: meta-analysis of animal models with acute myocardial infarction |
| Q36411656 | Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? |
| Q64066055 | Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis |
| Q35508337 | Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients |
| Q26853571 | Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes |
| Q34187551 | Benefits of statin therapy and compliance in high risk cardiovascular patients |
| Q36921139 | Biological activities of oxygenated sterols: Physiological and pathological implications |
| Q42027903 | Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways |
| Q70197756 | Blocking 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase with ML-236B Enhances the Plasma Cortisol Response to Adrenocorticotropin in Patients with Hypercholesterolemia |
| Q28077605 | Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage |
| Q64103456 | CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins? |
| Q36193205 | Can cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved? |
| Q125770814 | Can we achieve ESC 2019 guidelines LDL-cholesterol target in Tunisia? |
| Q64110387 | Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study |
| Q67593700 | Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin |
| Q67518109 | Cholesterol inhibition, cancer, and coronary heart disease |
| Q36536175 | Cholesterol lowering for secondary prevention: what statin dose should we use? |
| Q44144956 | Cholesterol, 7-ketocholesterol and 25-hydroxycholesterol uptake studies and effect on 3-hydroxy-3-methylglutaryl-coenzyme a reductase activity in human fibroblasts |
| Q35034986 | Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis |
| Q36812806 | Clinical efficacy and safety of statins in managing cardiovascular risk |
| Q71857123 | Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients |
| Q71857138 | Clinical efficacy of fluvastatin in thelong-term treatment of familial hypercholesterolemia |
| Q36998040 | Clinical review: Statins and trauma--a systematic review |
| Q34733233 | Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. |
| Q39995392 | Colchicine inhibits hepatic cholesterol synthesis and microsomal 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA reductase) activity |
| Q36812752 | Combination therapy in cholesterol reduction: focus on ezetimibe and statins. |
| Q67969157 | Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants |
| Q36268257 | Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials |
| Q34566253 | Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits |
| Q67516491 | Coronary atheroma regression trials. MAAS Steering Committee |
| Q90164298 | Creatine as a Candidate to Prevent Statin Myopathy |
| Q64119852 | Critical Appraisal of Bidirectional Relationship between Periodontitis and Hyperlipidemia |
| Q34614726 | Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals |
| Q57463324 | Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA |
| Q28075647 | Curcumin: An effective adjunct in patients with statin-associated muscle symptoms? |
| Q33715404 | Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. |
| Q33643355 | Design considerations for an integrated microphysiological muscle tissue for drug and tissue toxicity testing |
| Q68100014 | Determination of SQ 33,600, a phosphinic acid containing HMG CoA reductase inhibitor, in human serum by high-performance liquid chromatography combined with ionspray mass spectrometry |
| Q68204603 | Determination of the novel hydroxymethyl glutaryl coenzyme A reductase inhibitor (RP 61969) and its dihydroxy acid hydrolysis product in human plasma by reversed-phase high-performance liquid chromatography |
| Q64079422 | Diagnosis and Management of Statin Intolerance |
| Q67990026 | Dietary management of patients with familial hypercholesterolaemia treated with simvastatin |
| Q64137045 | Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction |
| Q86424396 | Do statins cause dementia? |
| Q36392225 | Do statins have a role in preventing or treating sepsis? |
| Q24804153 | Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? |
| Q36008769 | Does short preoperative statin therapy prevent infectious complications in adults undergoing cardiac or non-cardiac surgery? A meta-analysis of 5 randomized placebo-controlled trials |
| Q46619477 | Drug tendon disorders |
| Q72034298 | Economics of lipid lowering with HMG CoA reductase inhibitors: To the editor |
| Q26851763 | Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis |
| Q35146964 | Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression |
| Q68252922 | Effect of HMG-CoA reductase inhibitors on the erythrocyte membrane |
| Q52564491 | Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis. |
| Q51589854 | Effect of Treatment With a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor on Fasting and Postprandial Plasma Lipoproteins and Cholesteryl Ester Transfer Activity in Patients with NIDDM |
| Q71857063 | Effect of fluvastatin for safely loweringatherogenic lipids in renal transplant patients receiving cyclosporine |
| Q36288478 | Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis |
| Q71835978 | Effect of humidity-dependent changes in crystal structure on the solid-state fluorescence properties of a new HMG-CoA reductase inhibitor |
| Q33672902 | Effect of perioperative statin therapy on renal outcome in patients undergoing cardiac surgery: A meta-analysis of randomized controlled trials |
| Q55231715 | Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on survival of AH130 hepatoma-bearing rats |
| Q67491559 | Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome |
| Q67582934 | Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients |
| Q34400201 | Effect of statin therapy on the progression of coronary atherosclerosis |
| Q33588706 | Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials |
| Q39031198 | Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. |
| Q61445076 | Effectiveness of long-term using statins in COPD - a network meta-analysis |
| Q67928422 | Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin |
| Q41599680 | Effects of 32-oxygenated lanosterol derivatives on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis from 24,25-dihydrolanosterol |
| Q58123832 | Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials |
| Q36999320 | Effects of ML-236B (Compactin) on Sterol Synthesis and Low Density Lipoprotein Receptor Activities in Fibroblasts of Patients with Homozygous Familial Hypercholesterolemia |
| Q49941044 | Effects of Plasma Lipids and Statins on Cognitive Function |
| Q64058659 | Effects of Preoperative Statin on Acute Kidney Injury After Off-Pump Coronary Artery Bypass Grafting |
| Q36988655 | Effects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-compliant Systematic Review and Meta-Analysis |
| Q35685253 | Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis |
| Q41099372 | Effects of a new calf thymus protein on 3-hydroxy-3-methylglutaryl-CoA reductase activity in rat (Rattus bubalus) hepatocyte cells (BRL-3A) |
| Q71857189 | Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin |
| Q39402656 | Effects of atorvastatin on chronic subdural hematoma: A systematic review |
| Q71796557 | Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients |
| Q51587196 | Effects of fluvastatin on humanbiliary lipids |
| Q71857103 | Effects of fluvastatin on lipid profile andapolipoproteins in Chinese patients with hypercholesterolemia |
| Q53727939 | Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients |
| Q71857077 | Effects of flwastatin on growth of porcine and human vascular smooth muscle cells in vitro |
| Q42271125 | Effects of n-(4-methylbenzylthiocarbonyl)-l-phenylalanine (kf 1492), a new phenylalanine derivative, on lipid synthesis in vivo inhibition of hepatic cholesterol synthesis and 3-hydroxy-3-methylglutaryl-Co a reductase |
| Q36107562 | Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis |
| Q64109366 | Effects of statins on anxiety and depression in patients with asthma-chronic obstructive pulmonary disease overlap syndrome |
| Q24650533 | Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit |
| Q64103448 | Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance |
| Q37167517 | Efficacy and safety of rosuvastatin in the management of dyslipidemia |
| Q46369231 | Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment |
| Q43087729 | Efficacy and safety of statins in the treatment of diabetic dyslipidemia |
| Q42276927 | Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia |
| Q38904855 | Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis |
| Q26797400 | Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials |
| Q39418338 | Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials |
| Q28068027 | Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials |
| Q37202135 | Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk |
| Q64328607 | Esterification of HDL-cholesterol is Decreased in Diabetes Mellitus and CAD and Enhanced Following Treatment with Statins |
| Q64888369 | Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. |
| Q70797550 | Evidence indicating that inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by low density lipoprotein or by 25-hydroxycholesterol requires mediator protein(s) with rapid turnover rate |
| Q37714588 | Evidence-based goals in LDL-C reduction |
| Q95592165 | Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality |
| Q67913659 | Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin |
| Q26828489 | Familial hypercholesterolemia: present and future management |
| Q67415064 | Fatty acyl-CoA inhibition of beta-hydroxy-beta-methylglutaryl-CoA reductase activity |
| Q68132453 | Feedback-type inhibition of activity of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ubiquinone |
| Q37653029 | Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy |
| Q28284661 | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
| Q37202140 | Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives |
| Q71857196 | Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency |
| Q71857170 | Fluvastatin in severe hypercholesterolemia:Analysis of a clinical trial database |
| Q33600357 | From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine |
| Q36108705 | HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma |
| Q36694187 | HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal Macrophages |
| Q35664623 | HMG-CoA reductase inhibitor use in the aged. A review of clinical experience |
| Q50933570 | HMG-CoA reductase kinase: measurement of activity by methods that preclude interference by inhibitors of HMG-CoA reductase activity or by mevalonate kinase |
| Q36080332 | Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention |
| Q44298497 | Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors |
| Q28318682 | Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors |
| Q51587187 | High-dose fluvastatin and bezafibratecombination treatment for heterozygous familial hypercholesterolemia |
| Q26853061 | High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis |
| Q28342422 | Hypocholesterolemic agents III: Inhibition of β‐hydroxy‐β‐methylglutaryl coenzyme a reductase by half acid esters of 1‐(4‐biphenylyl)pentanol |
| Q44415045 | Hypocholesterolemic agents IV: inhibition of beta-hydroxy-beta-methyglutaryl coenzyme A reductase by arylalkenyl and arylepoxy hydrogen succinates and glutarates |
| Q28334352 | Hypocholesterolemic agents V: Inhibition of beta-hydroxy-beta-methylglutaryl coenzyme A reductase by substituted 4-biphenylylalkyl carboxylic acids and methyl esters |
| Q43828929 | Hypocholesterolemic agents—VI. Serum cholesterol lowering activity of β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitors in rats |
| Q34636105 | Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase |
| Q34512091 | Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase |
| Q26783206 | Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies |
| Q34054471 | Impact of statins on cognitive deficits in adult male rodents after traumatic brain injury: a systematic review. |
| Q26801352 | Impact of statins on risk and survival of ovarian cancer |
| Q52014753 | Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease |
| Q71809356 | In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin* |
| Q41328818 | Inactivation of soluble 3-hydroxy-3-methylglutaryl CoA reductase by ATP |
| Q89501309 | Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities |
| Q67887869 | Influence of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Pravastatin, on Corticosteroid Metabolism in Patients with Heterozygous Familial Hypercholesterolemia |
| Q72935074 | Influence of mevalonate kinase on studies of the MgATP-dependent inactivator of 3-hydroxy-3-methylglutaryl coenzyme A reductase |
| Q39979392 | Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in hepatoma tissue culture cells by pure cholesterol and several cholesterol derivatives. Evidence supporting two distinct mechanisms.20l |
| Q36258094 | Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance |
| Q54253682 | Inhibition of cholesterol synthesis and cataract |
| Q67420430 | Inhibition of cholesterol synthesis by oxygenated sterols |
| Q72114031 | Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase |
| Q67685401 | Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
| Q40231567 | Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor |
| Q70966533 | Inhibition of membrane-bound hepatic 3 hydroxy-3 methyl glutaryl CoA reductase as the consequence of altered membrane fluidity |
| Q33980245 | Inhibition of polyisoprenoid and glycoprotein biosynthesis causes abnormal embryonic development |
| Q28320098 | Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones |
| Q44822440 | Inhibitors of sterol synthesis. 3 beta,25-dihydroxy-5 alpha-cholest-8(14)-en-15-one, an active metabolite of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one |
| Q67992281 | Inhibitors of sterol synthesis. Chemical syntheses and spectral properties of 26-oxygenated derivatives of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one and their effects on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in CHO-K1 cells |
| Q41130506 | Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs |
| Q67353601 | Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase |
| Q40428459 | Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors |
| Q37577161 | Intolerance to statins: mechanisms and management |
| Q41956974 | Is fat restriction needed with HMGCoA reductase inhibitor treatment? |
| Q28219702 | Is there a role of statins in the prevention of aortic biological prostheses degeneration |
| Q39263474 | Kinetic Analysis of the Reaction Catalyzed by Rat-Liver 3-Hydroxy-3-methylglutaryl-coenzyme-A Reductase Using Two Specific Inhibitors |
| Q41860338 | Lack of effect of clofibrate on hepatic HMG-CoA reductase activity in young swine in the postabsorptive state |
| Q71857117 | Lack of interaction between fluvastatin andoral nypoylycemie agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus |
| Q57170030 | Lipid Screening, Action, and Follow-up in Children and Adolescents |
| Q68235240 | Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double-blind placebo-controlled study |
| Q49792187 | Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies |
| Q33574532 | Lipid, blood pressure and kidney update 2013. |
| Q26827432 | Lipid-lowering therapy: who can benefit? |
| Q44390534 | Lipoprotein particle analysis comparing simvastatin and fenofibrate |
| Q67706454 | Lipoproteins and arterial smooth muscle cells: regulation of cellular metabolism by swine lipoproteins |
| Q67932629 | Long-term effects of simvastatin in familial dysbetalipoproteinaemia |
| Q67856224 | Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia |
| Q72899652 | Lowering Plasma Cholesterol by Raising LDL Receptors |
| Q68025899 | Lupuslike syndrome associated with simvastatin |
| Q41940694 | Lysosome inhibitors enhance the ability of cyclic AMP-elevating agents to induce the LDL receptor in human vascular smooth muscle cells |
| Q91406151 | Management of Lipid Abnormalities in Patients with Diabetes |
| Q48274059 | Management of Statin Intolerance in 2018: Still More Questions Than Answers |
| Q37167555 | Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. |
| Q36906018 | Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin |
| Q34068746 | Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. |
| Q37018964 | Management of hyperlipidemia with statins in the older patient |
| Q26752952 | Management of intracerebral hemorrhage--use of statins |
| Q37388209 | Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin |
| Q71878180 | Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis |
| Q94672123 | May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects? |
| Q42177559 | Mechanisms of action and efficacy of statins against influenza. |
| Q26992028 | Mechanisms of bone anabolism regulated by statins |
| Q35563904 | Medical ethics and the call for transparency |
| Q99201577 | Meta-analysis of Effect of Statins in Patients with COVID-19 |
| Q41594506 | Mevinolin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, suppresses enterocyte esterification of exogenous but not endogenous cholesterol |
| Q68351981 | Modification of cardiovascular risk factors |
| Q34685463 | Molecular mechanisms underlying the effects of statins in the central nervous system |
| Q27023343 | Muscular effects of statins in the elderly female: a review |
| Q38791719 | NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs |
| Q67743046 | New site-directed reversible inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase |
| Q67978724 | New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis |
| Q71869750 | No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and Warfarin |
| Q27026332 | Non-cardiovascular effects associated with statins |
| Q55011566 | Nonadherence to statins: individualized intervention strategies outside the pill box. |
| Q28076399 | Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia |
| Q28219321 | Ongoing clinical trials of the pleiotropic effects of statins |
| Q71857156 | Open-label study to assess the efficacy, safe, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia |
| Q26798119 | Optimizing Treatment of Familial Hypercholesterolemia in Children and Adolescents |
| Q45335752 | Outcome monitoring of fluvastatin in a Department of Veterans Affairs Lipid Clinic |
| Q28073319 | Overcoming Challenges With Statin Therapy |
| Q34720533 | Oyster mushroom (Pleurotus ostreatus) reduces the activity of 3-hydroxy-3-methylglutaryl CoA reductase in rat liver microsomes |
| Q91128138 | Parenteral systems for statin delivery: a review |
| Q71857110 | Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors |
| Q28066001 | Patient-Centered Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified Studies |
| Q36766937 | Perioperative use of statins in noncardiac surgery. |
| Q28080692 | Perspective of synaptic protection after post-infarction treatment with statins |
| Q34680467 | Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins |
| Q42678980 | Pharmacokinetics of the combination of fluvastatin and gemfibrozil |
| Q27020935 | Phenotype standardization for statin-induced myotoxicity |
| Q21246037 | Pitavastatin in cardiometabolic disease: therapeutic profile |
| Q34999753 | Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus |
| Q34633506 | Pleiotropic effects of pitavastatin |
| Q37248230 | Pleiotropic effects of statins in atrial fibrillation patients: the evidence |
| Q30239075 | Pleiotropic effects of statins in the perioperative setting |
| Q42277319 | Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin |
| Q90732025 | Potential Effect of Statins on Mycobacterium tuberculosis Infection |
| Q39440767 | Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia |
| Q68294767 | Pravastatin: a hydrophil and liver sparing CSE-inhibitor. European Atherosclerosis Congress. 10 October 1990, Cagliari, Sardinien |
| Q36748541 | Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods |
| Q33972551 | Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey |
| Q38536886 | Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review and Meta-Analysis |
| Q43417176 | QSAR study of HMGR inhibitors: 7-(heteroaryl)-3,5-dihydroxy-6-heptenoic (-heptanoic) acids |
| Q30244632 | Racial Differences in the Cholesterol-Lowering Effect of Statin |
| Q67573552 | Rearrangement of unsaturated 2,4-O-benzylidenehexitol derivatives into C-glycosylbenzene derivatives |
| Q37230464 | Reducing morbidity and mortality in high risk patients with statins |
| Q53861547 | Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase by endogenous sterol synthesis in cultured intestinal mucosa |
| Q35648346 | Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis |
| Q34584965 | Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin |
| Q36835823 | Relative safety profiles of high dose statin regimens |
| Q68140237 | Response to treatment with simvastatin in a compound FH heterozygote |
| Q38502694 | Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials |
| Q40210620 | Reversible Modulation of Rat Liver 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase: Evidence for an Interconvertible System |
| Q67242326 | Reversible inactivation of 3-hydroxy-3-methylglutaryl coenzyme a reductase: Reductase kinase and mevalonate kinase are separate enzymes |
| Q28084971 | Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders |
| Q36168823 | Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins |
| Q89156300 | Role of Bisphosphonates in Vascular calcification and Bone Metabolism: A Clinical Summary |
| Q92179307 | Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients |
| Q41633477 | Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis |
| Q46415777 | Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation |
| Q33610801 | Should all diabetic patients be treated with a statin? |
| Q67856221 | Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment |
| Q67767755 | Simvastatin and side effects |
| Q72076676 | Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model |
| Q71814893 | Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications |
| Q67966273 | Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia |
| Q67902768 | Simvastatin in the treatment of hypercholesterolemia |
| Q35100483 | Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics |
| Q41003110 | Specific, reversible inactivation of yeast β-hydroxy-β-methylglutraryl-CoA reductase by CoA |
| Q64075602 | Statin Intolerance and Suboptimal Statin Therapy |
| Q36185896 | Statin Intolerance: the Clinician's Perspective |
| Q64076358 | Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes |
| Q24602803 | Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP? |
| Q36315609 | Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis |
| Q34350375 | Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States |
| Q36888713 | Statin diabetogenicity: guidance for clinicians |
| Q59336382 | Statin drugs to reduce breast cancer recurrence and mortality |
| Q38430744 | Statin intolerance: diagnosis and remedies |
| Q37443179 | Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review |
| Q36841934 | Statin tolerability: In defence of placebo-controlled trials |
| Q33587600 | Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis |
| Q28082068 | Statin use and breast cancer survival and risk: a systematic review and meta-analysis |
| Q124719468 | Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies |
| Q43238301 | Statin use and risk of developing diabetes: results from the Diabetes Prevention Program |
| Q39295852 | Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis |
| Q28083004 | Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management |
| Q26822368 | Statin-induced lung injury: diagnostic clue and outcome |
| Q35561412 | Statins STAT for (over)ventilated patients? |
| Q90283434 | Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation |
| Q38285483 | Statins and Cataracts--a visual insight |
| Q64062792 | Statins and Inflammation: New Therapeutic Opportunities in Psychiatry |
| Q104492966 | Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019? |
| Q101116586 | Statins and SARS-CoV-2 disease: Current concepts and possible benefits |
| Q64284086 | Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use |
| Q34086279 | Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials |
| Q39413658 | Statins and the Brain: More than Lipid Lowering Agents? |
| Q36125495 | Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study |
| Q36088110 | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. |
| Q24806116 | Statins as modulators of bone formation |
| Q38162189 | Statins as modulators of regulatory T-cell biology. |
| Q26864029 | Statins as potential therapeutic drug for asthma? |
| Q64096399 | Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews |
| Q26776067 | Statins in Asthma: Potential Beneficial Effects and Limitations |
| Q27010638 | Statins in cardiometabolic disease: what makes pitavastatin different? |
| Q39126237 | Statins in conditions other than hypocholesterolemic effects for chronic subdural hematoma therapy, old drug, new tricks? |
| Q26998966 | Statins in heart failure: do we need another trial? |
| Q21261910 | Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials |
| Q53305494 | Statins in neurological disorders: mechanisms and therapeutic value. |
| Q33244366 | Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trials |
| Q92216130 | Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence |
| Q64051973 | Statins in the perioperative period |
| Q64101992 | Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection |
| Q34461476 | Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms |
| Q30357923 | Statins, bugs and prophylaxis: intriguing possibilities. |
| Q57105348 | Statins: a role in breast cancer therapy? |
| Q73321406 | Steinerts disease and statins |
| Q39965965 | Steroid Requirements for Suppression of HMG CoA Reductase Activity in Cultured Human Fibroblasts |
| Q46342569 | Structural Basis for the Barrier Abnormality Following Inhibition of HMG CoA Reductase in Murine Epidermis |
| Q67485164 | Subacute Toxicity of a Halogenated Pyrrole Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor in Wistar Rats |
| Q37134266 | Subclinical atherosclerosis: what it is, what it means and what we can do about it. |
| Q67590772 | Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats |
| Q36469426 | Sugar, soap and statins--an unlikely recipe for the critically ill. |
| Q40138901 | Suppression of 3-Hydroxy-3-Methylglutaryl coenzyme a reductase activity and of incorporation of acetate into cholesterol in homozygous hypercholesterolemic fibroblasts by ferritin-low density lipoprotein conjugates |
| Q40204330 | Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins |
| Q68471921 | Suppression of hepatic HMG-CoA reductase activity by beta-muricholic acid in mice fed a diet containing cholesterol and cholic acid |
| Q28147233 | Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids |
| Q28318823 | Synthesis and biological evaluation of dihydroeptastatin, a novel inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase |
| Q68234207 | Synthesis of 2,6,7-trideoxy-7-C-(2,4-dichlorophenyl)-d-xylo-heptonic acid and 6-(2,4-dichlorophenyl)-d-xylo-2,3,4-trihydroxyhexanesulfonic acid |
| Q47139916 | Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia |
| Q34531972 | Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality |
| Q35946029 | Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma |
| Q64284712 | Targeting angiogenesis in Duchenne muscular dystrophy |
| Q37019920 | Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin |
| Q39277616 | The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature |
| Q61812831 | The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis |
| Q67864713 | The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans |
| Q33571213 | The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences |
| Q59813666 | The Question of a Role for Statins in Age-Related Macular Degeneration |
| Q55515152 | The Role of n-3 Long Chain Polyunsaturated Fatty Acids in Cardiovascular Disease Prevention, and Interactions with Statins. |
| Q30320333 | The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells |
| Q24646234 | The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials |
| Q38478019 | The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report. |
| Q28188527 | The discovery and development of HMG-CoA reductase inhibitors |
| Q30914775 | The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials |
| Q58556126 | The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials |
| Q26786733 | The effect of statins on average survival in randomised trials, an analysis of end point postponement |
| Q38499265 | The effect of statins on cancer cells--review |
| Q36265724 | The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research |
| Q37072692 | The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis |
| Q58802086 | The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials |
| Q34498512 | The impact of statins on psychological wellbeing: a systematic review and meta-analysis |
| Q66930594 | The inhibitory effect of ATP on HMGCoA reductase |
| Q28292087 | The origin of the statins. 2004 |
| Q26829941 | The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials |
| Q28071340 | The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study (CROS) |
| Q36536154 | The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation |
| Q24806198 | The role of statins as potential targets for bone formation |
| Q26823131 | The role of statins in erectile dysfunction: a systematic review and meta-analysis |
| Q34562123 | The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis |
| Q26778906 | The stats are in: an update on statin use in COPD |
| Q26849333 | Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia |
| Q64113702 | Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study |
| Q67651545 | Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by the antibiotic citrinin |
| Q71857088 | Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage |
| Q27006481 | Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses |
| Q91523880 | Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach |
| Q91037895 | Treatment with Statins in Elderly Patients |
| Q64239364 | Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014 |
| Q28077243 | Triple-negative breast cancer: is there a treatment on the horizon? |
| Q26828967 | Ultrasound assessment of carotid plaque echogenicity response to statin therapy: a systematic review and meta-analysis |
| Q34411415 | Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis |
| Q26741705 | Unmet Needs in LDL-C Lowering: When Statins Won't Do! |
| Q40476568 | Update on the treatment of hypercholesterolemia, with a focus on hmg‐coa reductase inhibitors and combination regimens |
| Q36437128 | Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis |
| Q27003173 | Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients |
| Q34485974 | Use of statins in lower extremity artery disease: a review |
| Q37031371 | Utilizing enoxaparin in the management of STEMI. |
| Q34828582 | When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins |
| Q36013031 | Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter? |
| Q68235247 | Worldwide experience with simvastatin/lovastatin |
| Q44481761 | Zocor, the postmarketing experience |
| Q38536886 | Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review and Meta-Analysis | instance of | P31 |
| Q8816931 | Category:Statins | category's main topic | P301 |
| Q21118078 | response to statin | has part(s) | P527 |
| Q55785927 | immune-mediated necrotizing myopathy | has cause | P828 |